First Mercantile Trust Co. Has $758,000 Position in Hologic, Inc. (NASDAQ:HOLX)
First Mercantile Trust Co. continued to hold its stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,700 shares of the medical equipment provider’s stock at the end of the second quarter. First Mercantile Trust Co.’s holdings in Hologic were worth $758,000 as of its most recent filing with the SEC.
Other large investors have also bought and sold shares of the company. Chevy Chase Trust Holdings Inc. raised its stake in Hologic by 3.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 240,769 shares of the medical equipment provider’s stock valued at $10,245,000 after buying an additional 8,289 shares in the last quarter. Gulf International Bank UK Ltd raised its stake in Hologic by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 74,164 shares of the medical equipment provider’s stock valued at $3,155,000 after buying an additional 1,100 shares in the last quarter. National Pension Service raised its stake in Hologic by 55,168.1% in the first quarter. National Pension Service now owns 244,285 shares of the medical equipment provider’s stock valued at $10,433,000 after buying an additional 243,843 shares in the last quarter. Fox Run Management L.L.C. raised its stake in Hologic by 117.2% in the first quarter. Fox Run Management L.L.C. now owns 12,600 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 6,800 shares in the last quarter. Finally, Graybill Bartz & Assoc Ltd. raised its stake in Hologic by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 59,185 shares of the medical equipment provider’s stock valued at $2,518,000 after buying an additional 885 shares in the last quarter. 94.46% of the stock is owned by institutional investors.
Hologic, Inc. (NASDAQ HOLX) opened at 38.20 on Friday. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The stock has a 50 day moving average price of $43.73 and a 200 day moving average price of $42.89. The stock has a market cap of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the prior year, the firm earned $0.51 EPS. The business’s revenue was up 12.4% on a year-over-year basis. On average, analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.
WARNING: This news story was first reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/13/first-mercantile-trust-co-has-758000-position-in-hologic-inc-nasdaqholx.html.
Several equities research analysts recently issued reports on HOLX shares. Canaccord Genuity reissued a “buy” rating and set a $53.00 price objective on shares of Hologic in a research note on Tuesday, May 9th. Stifel Nicolaus raised their price target on Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, May 11th. BTIG Research restated a “buy” rating and set a $47.00 price target on shares of Hologic in a research report on Sunday, May 14th. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Finally, Jefferies Group LLC set a $49.00 price target on Hologic and gave the company a “buy” rating in a research report on Sunday, May 28th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. Hologic has a consensus rating of “Buy” and an average price target of $48.64.
In related news, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence M. Levy sold 9,076 shares of the stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total transaction of $388,452.80. Following the completion of the transaction, the director now directly owns 43,165 shares of the company’s stock, valued at approximately $1,847,462. The disclosure for this sale can be found here. Insiders have sold a total of 60,627 shares of company stock valued at $2,632,911 in the last three months. Insiders own 0.79% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.